Skip to main
NBIX

Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences (NBIX) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 45%
Buy 41%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Neurocrine Biosciences is poised for success as their current portfolio of drugs is performing well, and they have a strong pipeline of drug candidates in development which could provide significant revenue growth in the future. Additionally, their recent acquisition of Soleno could further strengthen their product portfolio and revenue potential. The company also appears to be well-integrated in sustainability initiatives and has a strong governance structure to support their efforts in this area. However, there are potential risks to consider, such as potential setbacks in R&D or commercialization, emergence of new competitors, and financing issues. Overall, the company's positive growth outlook and strong position in the biopharmaceutical industry make them a promising investment option.

Bears say

Neurocrine Biosciences is facing potential downside risks due to slow growth in key products, failure of pipeline assets, and increased competition leading to a loss of market share and decline in pricing power. While Ingrezza still has potential for growth in tardive dyskinesia, reaching peak sales in 2029, there are risks such as the emergence of side effects and discounted pricing. The recent 1Q26 financial results exceeded expectations, but there are still risks to consider such as stability of Ingrezza sales, potential plateau in Crenessity sales, and potential headwinds in the competitive landscape.

Neurocrine Biosciences (NBIX) has been analyzed by 22 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 41% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neurocrine Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neurocrine Biosciences (NBIX) Forecast

Analysts have given Neurocrine Biosciences (NBIX) a Buy based on their latest research and market trends.

According to 22 analysts, Neurocrine Biosciences (NBIX) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $200.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $200.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neurocrine Biosciences (NBIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.